TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Deviation of TKA alignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Virologic suppression change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluid responsiveness prediction reliability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fugl-Meyer motor function assessment of upper limb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in glucose average and variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in neurodevelopmental status as measured by Bayley Scales of Infant and Toddler Development, 3rd Edition (BSID-III) scaled scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in physical functioning as measured by Pediatric Quality of Life Inventory (PedsQL) scale scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in emotional functioning as measured by Pediatric Quality of Life Inventory (PedsQL) scale scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Completion of parenteral antibiotic therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: clinically-driven revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: 3 Year Recurrence Rate
Endpoint domain: Mortality/survival
Primary endpoint: Days of Use of Most Problematic Drug
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: high amplitude propagative contractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Major morbidity
Endpoint domain: Mortality/survival
Primary endpoint: Plasma FGF21 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of Participant Retention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: System Usability Scale (SUS) >68
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Client Satisfaction Questionnaire (CSQ-8) Score of ≥17
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Level of knowledge about earthquakes
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in urgency incontinence episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion recovery from diagnosis of IBS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinical PVC events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recurrence of febrile seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of epilepsy following febrile seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Frequency of challenging behavior
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Functional Lower Extremity Force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatic transaminases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Jebsen Hand Function Test (JHFT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duruoz Hand Index (DHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Michigan Hand Outcome questionnaire (MHQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: State-trait Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Histological quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amygdala BOLD fMRI activation to fearful vs neutral faces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Montreal Cognitive Assessment (MoCA) scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Sensitivity of HS_RDT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of HS_RDT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Visual Analogue scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Knee Injury and Osteoarthritis Outcome Score (KOOS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiological changes in Magnetic resonance observation of cartilage repair tissue (MOCART 2.0)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of IV midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of oral midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of medical advices with follow-up completed in epidemic condition
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of medical advices with follow-up completed in summer
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Define Toxicities - CTCAE v5.0
Endpoint domain: Adverse events/effects
Primary endpoint: Combined Stories Test (COST)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Social Knowledge Test (SKT)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Penn Emotion Recognition Task (ER-40)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Interpersonal, Personal and Situational Attributions Questionnaire (IPSAQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mortality in preterm newborns
Endpoint domain: Mortality/survival
Primary endpoint: Adverse Events as assessed by CTCAE v5.0
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical outcomes on MAKE30
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Respiratory particle production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Intended uptake of EAC screening
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Woman Abuse Screening Tool (WAST)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of inflammatory status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of severe AE graded according to the CTCAE v.5
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of chemotherapy dose interruption, dose modification, dose discontinuation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Ventilation to carbon dioxide production slope
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time needed to explore heart
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma IL-1β concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline average pain intensity at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline average pain intensity at 48 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline highest pain intensity at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline highest pain intensity at 48 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline pain frequency at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline pain frequency at 48 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complexity of general movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variability of general movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluidity of general movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FIBTEM MCF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FIBTEM CT and CFT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EXTEM CT and CFT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Computerized glove software
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of autonomic dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Area under plasma concentration (AUC) 0 to ∞
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under plasma concentration (AUC) 0 to t
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The range of motion scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Non epileptic seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Cognitive Gains
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Correlation with mortality
Endpoint domain: Mortality/survival
Primary endpoint: VTA - mesolimbic system functional connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Peak Edi
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body Fat Caliper Mass Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Countermovement Jump Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression free survival of SHH-2 infant and young child medulloblastoma patients
Endpoint domain: Mortality/survival
Primary endpoint: Progression free survival of SHH-1 infant medulloblastoma patients
Endpoint domain: Mortality/survival
Primary endpoint: Progression free survival of G3/G4 infant medulloblastoma patients
Endpoint domain: Mortality/survival
Primary endpoint: Change in lower limb joint angles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in lower limb joint angular velocities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in joint moments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: newly-diagnosed prostate cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in nasal congestion as assessed by the peak nasal inspiratory flow (PNIF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in levels of type 2 cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: changes in Edinburgh Postnatal Depression Scale scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: change in maternal-infant bonding scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: utilization of behavioral health/psychology/psychiatry services during pregnancy and postpartum
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: use of psychiatry medications during and after pregnancy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of radiotherapy-related gastrointestinal adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of radiotherapy-related urogenital tract adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of HIV testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average daily step-count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of falls in the previous three months (self-reported)
Endpoint domain: Adverse events/effects
Primary endpoint: Timed Up and Go Test (Walking speed; metres per second)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Two Minute Free Walking Test (Walking Speed; metres per second)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exercise Self-efficacy Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: range of motion (active flexion and extension)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Incidence of peri-hepatic adhesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of hospitalisation days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Investigator Live Assessment (Dynamic)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and severity of Treatment Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Ventilation strategy failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transient tachypnea of newborns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Fetal acidosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of opioid tablets used daily
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Abundance of Fusobacterium nucleatum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abundance of Campylobacter rectus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abundance of Prevotella intermedia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abundance of Aggregatinacter actinomycetemcomitans
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abundance of Porphyromonas gingivalis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abundance of Tannerella forsythia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ultrafiltration volume of device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ultrafiltration speed of device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of AI in diabetic retinopathy screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Efficiency of AI in diabetic retinopathy screening
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Crevicular fluid volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Numeric rating scale pain score at movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life function
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of participants with any dose-limiting toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of correctly named pictures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of correctly generated category members
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Flow Cytometry analyses of Peripheral Blood Mononuclear Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Anti HLA B-cell ELISpot response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Flow Cytometry analyses of medullary cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in analyses of RNA expression on renal histology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: hearing function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of new AF during index hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of new AF burden during index hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of new AF during 3 months follow-up after index hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of new AF burden during 3 months follow-up after index hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of adverse events related to PDL device
Endpoint domain: Adverse events/effects
Primary endpoint: Geriatric Depression Scale Short Form
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 5 times sit and stand test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mini Mental Status Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Accuracy of telemedicine diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Convalescence Symptom Assessment Scale for Esophagectomy patients
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Lung cancer metastasis prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Bioindicators of treatment effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Macular Pigment Optical Density (MPOD) Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Field Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clinical outcomes related to biomarker levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of the refractive error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of the rotational stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Appendicular Lean Mass (ALM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Proteomic Profile: Chronic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Proteomic Profile: Acute
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Real-World Objective Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve from Time Zero to Time of Last Quantifiable Concentration (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve from Time Zero to Infinity (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change From Baseline Ct Viral Targets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 3 enteritis
Endpoint domain: Adverse events/effects
Primary endpoint: LUS change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hip problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: knee problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Level of shivering
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Magnitude of neutralizing antibody response against YF-17D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Magnitude of neutralizing antibody response against QIV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: H-CEUS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No incidence of treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Visual Analogue Scale - VAS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Six Point Engorgement Scale - SPE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breastfeeding Self-Efficacy Scale - BSES
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of subjects receiving colonoscopy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of subjects suffering early colorectal cancer
Endpoint domain: Mortality/survival
Primary endpoint: Sensitivity and specificity of the model in the diagnosis of colorectal cancer and adenoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Overall satisfaction using Visual Analogue Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proportion of plasma meropenem levels ≥ 4 mg/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of sites successfully inspected during endoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: 6 Minute Walk Test (distance in metre)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breath limonene value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leisure time physical activity level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes